Entrada Therapeutics, Inc. (TRDA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29384C1080
Entrada Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 25.42 m USD |
| Operating income | -157.90 m USD |
| EBIT | -142.83 m USD |
| Net income | -143.75 m USD |
| Diluted EPS – continuing operations | -3.47 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
More stocks
- Top Bright Holding Co Ltd (8499.TW)
- Skinkandy Limited (SK1.AX)
- APARTMENT INVESTMENT & MANAGEMENT CO (AIV)
- APPLIED ENERGETICS, INC. (AERG)
- Cica-Huntek Chemical Technology Taiwan Co., Ltd. (6725.TWO)
- ToolGen Inc. (199800.KQ)
- San Juan Basin Royalty Trust (SJT)
- TTFB Co Ltd (2729.TWO)
- Imperial Petroleum Inc (IMPP)
- TOYO Co., Ltd Ordinary Shares (TOYO)
- Polaris Infrastructure Inc (PIF.TO)
- A Plus Asset Advisor Co Ltd (244920.KS)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.